Balaxi Pharma
Balaxi Pharma Q1 FY27: Revenue ₹80.68 Cr, PAT ₹1.29 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Balaxi Pharma's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). EBITDA for Q1 FY27: ₹4.66 crore, a 12.4% increase YoY from ₹4.15 crore in Q1 FY26.
From Balaxi Pharma's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20).
- Q1 FY27 Profit After Tax increased to ₹1.29 crore from ₹0.29 crore YoY, PAT margin improved by 120 bps to 1.6% (Page 20).
- EBITDA for Q1 FY27 rose 12.4% YoY to ₹4.66 crore (Page 20).
- Management outlook highlights positive revenue growth and improved profitability with further earnings potential as operating leverage and strategic initiatives mature (Page 19).
- The company expects expansion in institutional business, geographic markets (Africa and Latin America), and commercialization of the manufacturing facility to drive future growth (Page 19).
2 more points from Balaxi Pharma's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Balaxi Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Balaxi commissioned its first pharmaceutical formulation plant at a Pharma SEZ near Hyderabad, focusing on General Oral Solid Dosage (OSD) formulations for Latin America and Africa markets.
- The facility enables backward integration of the supply chain, previously outsourced to contract manufacturing.
- Commercial production at the Hyderabad facility has commenced, with approvals for 31 commercial products.
- The company is progressing towards WHO-GMP certification for the facility to enhance manufacturing credentials and unlock growth opportunities.
- The plant targets production scaling aligned with market demand and aims to improve regulatory processes and reduce time-to-market for new launches.
2 more points from Balaxi Pharma's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Balaxi Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Balaxi Pharma's call on order book
Pro opens every point from 15K+ earnings calls
Balaxi Pharma — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹73 Cr, net profit ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Balaxi Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Trident Lifeline (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Arthneeti Pro · Annual
Balaxi Pharma and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Balaxi Pharma Q1 FY27 results?
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). EBITDA for Q1 FY27: ₹4.66 crore, a 12.4% increase YoY from ₹4.15 crore in Q1 FY26.
What is Balaxi Pharma share price analysis?
Balaxi Pharma currently shows a neutral. The stock trades at a P/E of 50.3 with a market cap of ₹122 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaxi Pharma planning capital expenditure?
Balaxi commissioned its first pharmaceutical formulation plant at a Pharma SEZ near Hyderabad, focusing on General Oral Solid Dosage (OSD) formulations for Latin America and Africa markets.
Keep Balaxi Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.